JP2024518555A5 - - Google Patents

Info

Publication number
JP2024518555A5
JP2024518555A5 JP2023570166A JP2023570166A JP2024518555A5 JP 2024518555 A5 JP2024518555 A5 JP 2024518555A5 JP 2023570166 A JP2023570166 A JP 2023570166A JP 2023570166 A JP2023570166 A JP 2023570166A JP 2024518555 A5 JP2024518555 A5 JP 2024518555A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
formula
acceptable salt
propionylpyridine
cyclopropanecarboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023570166A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024518555A (ja
JP7818623B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/029117 external-priority patent/WO2022241174A1/en
Publication of JP2024518555A publication Critical patent/JP2024518555A/ja
Publication of JP2024518555A5 publication Critical patent/JP2024518555A5/ja
Application granted granted Critical
Publication of JP7818623B2 publication Critical patent/JP7818623B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023570166A 2021-05-14 2022-05-13 置換ヘテロ環化合物 Active JP7818623B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163188498P 2021-05-14 2021-05-14
US63/188,498 2021-05-14
US202263318508P 2022-03-10 2022-03-10
US63/318,508 2022-03-10
PCT/US2022/029117 WO2022241174A1 (en) 2021-05-14 2022-05-13 Substituted heterocyclic compounds

Publications (3)

Publication Number Publication Date
JP2024518555A JP2024518555A (ja) 2024-05-01
JP2024518555A5 true JP2024518555A5 (cg-RX-API-DMAC7.html) 2025-05-21
JP7818623B2 JP7818623B2 (ja) 2026-02-20

Family

ID=81927791

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023570166A Active JP7818623B2 (ja) 2021-05-14 2022-05-13 置換ヘテロ環化合物

Country Status (12)

Country Link
US (2) US11884650B2 (cg-RX-API-DMAC7.html)
EP (1) EP4337648B1 (cg-RX-API-DMAC7.html)
JP (1) JP7818623B2 (cg-RX-API-DMAC7.html)
KR (1) KR20240008338A (cg-RX-API-DMAC7.html)
AU (1) AU2022272725A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023023726A2 (cg-RX-API-DMAC7.html)
CA (1) CA3218579A1 (cg-RX-API-DMAC7.html)
ES (1) ES3059456T3 (cg-RX-API-DMAC7.html)
IL (1) IL308422A (cg-RX-API-DMAC7.html)
MX (1) MX2023013351A (cg-RX-API-DMAC7.html)
TW (1) TW202311248A (cg-RX-API-DMAC7.html)
WO (1) WO2022241174A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN122520625A (zh) 2020-12-22 2026-08-07 益方生物科技(上海)股份有限公司 杂芳基化合物及其制备方法和用途
US12668594B2 (en) 2020-12-23 2026-06-30 Sudo Biosciences Limited TYK2 inhibitors and uses thereof
IL305119A (en) 2021-02-19 2023-10-01 Sudo Biosciences Ltd Tyk2 inhibitors and uses thereof
TW202302583A (zh) 2021-02-19 2023-01-16 英商蘇多生物科學有限公司 Tyk2抑制劑及其用途
KR20230159421A (ko) 2021-02-19 2023-11-21 수도 바이오사이언시즈 리미티드 Tyk2 억제제 및 이의 용도
EP4337650A1 (en) * 2021-05-14 2024-03-20 Bristol-Myers Squibb Company Substituted heterocyclic compounds
US20240317718A1 (en) * 2021-05-14 2024-09-26 Bristol-Myers Squibb Company Substituted heterocyclic compounds
KR20240007242A (ko) * 2021-05-14 2024-01-16 브리스톨-마이어스 스큅 컴퍼니 치환된 헤테로시클릭 화합물
CN117263913A (zh) 2022-06-20 2023-12-22 益方生物科技(上海)股份有限公司 杂芳基化合物、固体形式、制备方法及其用途
CN118812511A (zh) * 2023-04-21 2024-10-22 浙江文达医药科技有限公司 作为tyk2抑制剂的杂环化合物及合成和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2922841B8 (en) * 2012-11-08 2017-08-02 Bristol-Myers Squibb Company Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
RS66346B1 (sr) 2018-10-22 2025-01-31 Alumis Inc Inhibitori tyk2 i njihova upotreba
KR102858043B1 (ko) * 2018-10-30 2025-09-10 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn-알파의 조정과 관련된 상태의 치료를 위한 아미드-치환된 헤테로시클릭 화합물
US20230295119A1 (en) 2020-04-14 2023-09-21 Gossamer Bio Services, Inc. Substituted pyridines for the treatment of inflammatory diseases
PE20250262A1 (es) 2021-05-14 2025-01-29 Bristol Myers Squibb Co Compuestos heterociclicos sustituidos
EP4337650A1 (en) 2021-05-14 2024-03-20 Bristol-Myers Squibb Company Substituted heterocyclic compounds
US20240317718A1 (en) 2021-05-14 2024-09-26 Bristol-Myers Squibb Company Substituted heterocyclic compounds
KR20240007242A (ko) 2021-05-14 2024-01-16 브리스톨-마이어스 스큅 컴퍼니 치환된 헤테로시클릭 화합물

Similar Documents

Publication Publication Date Title
JP2024518791A5 (cg-RX-API-DMAC7.html)
JP2024518792A5 (cg-RX-API-DMAC7.html)
EP2890375B1 (en) Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
JP6466348B2 (ja) スルファモイル−アリールアミドおよびb型肝炎を処置するための医薬品としてのその使用
JP2024518554A5 (cg-RX-API-DMAC7.html)
JP2022081661A5 (cg-RX-API-DMAC7.html)
JP2024516033A5 (cg-RX-API-DMAC7.html)
TWI500616B (zh) 新穎之雙環吡啶酮
RU2356893C2 (ru) Ингибиторы фосфодиэстеразы 4
JP2019506430A5 (cg-RX-API-DMAC7.html)
JP2008504266A5 (cg-RX-API-DMAC7.html)
US20120077854A1 (en) Compositions and methods for modulating retinol binding to retinol binding protein 4 (rbp4)
JP2021515004A5 (cg-RX-API-DMAC7.html)
JP2024517498A5 (cg-RX-API-DMAC7.html)
JP2022512736A5 (cg-RX-API-DMAC7.html)
EP4457222A2 (en) Nitric oxide releasing prodrugs of mda and mdma
JP2012518634A5 (cg-RX-API-DMAC7.html)
EA031041B1 (ru) Соединения 2,3,4,5-тетрагидропиридин-6-амин и 3,4-дигидро-2h-пиррол-5-амин - ингибиторы бета-секретазы
RU2007147344A (ru) Новые производные 2-азетидинона для лечения гиперлипидемических заболеваний
JP2024512818A5 (cg-RX-API-DMAC7.html)
CN106164064A (zh) 作为阿立新受体拮抗剂的取代环戊烷、四氢呋喃和吡咯烷
JP2026503618A5 (cg-RX-API-DMAC7.html)
JP2006512321A5 (cg-RX-API-DMAC7.html)
JP2008519783A5 (cg-RX-API-DMAC7.html)
CA2663080A1 (fr) Derives de pyrrolizine, indolizine et quinolizine, leur preparation et leur application en therapeutique.